ref_name,rx_name,control_iso_name,iso_name,section,assay_name,potency_type,fold_cmp,fold,resistance_level,ineffective,cumulative_count,date_added
FDA22,Bebtelovimab,Wuhan-Hu-1,S:444N,"Mar 2022, Page 12, antiviral resistance, paragraph 2",VLP,IC50,>,1901,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,S:444Q,"Mar 2022, Page 12, antiviral resistance, paragraph 2",VLP,IC50,>,208,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,S:444T,"Mar 2022, Page 12, antiviral resistance, paragraph 2",VLP,IC50,>,1814,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,S:445A,"Mar 2022, Page 12, antiviral resistance, paragraph 2",VLP,IC50,=,111,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,S:445F,"Mar 2022, Page 12, antiviral resistance, paragraph 2",VLP,IC50,=,369,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,S:445G,"Mar 2022, Page 12, antiviral resistance, paragraph 2",VLP,IC50,>,730,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,S:446D,"Mar 2022, Page 12, antiviral resistance, paragraph 2",VLP,IC50,=,69,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,S:446R,"Mar 2022, Page 12, antiviral resistance, paragraph 2",VLP,IC50,=,7,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,S:446V,"Mar 2022, Page 12, antiviral resistance, paragraph 2",VLP,IC50,=,8,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,S:499H,"Mar 2022, Page 12, antiviral resistance, paragraph 2",VLP,IC50,>,1606,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,S:499R,"Mar 2022, Page 12, antiviral resistance, paragraph 2",VLP,IC50,>,1870,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,S:499S,"Mar 2022, Page 12, antiviral resistance, paragraph 2",VLP,IC50,=,25,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,B.1.617.2 Spike:+446V,"Mar 2022, Page 12, antiviral resistance, paragraph 2",VLP,IC50,=,16.4,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,B.1.1.7 Spike,"Mar 2022, Page 13, antiviral resistance, Table 2",Pseudovirus,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,B.1.351 Spike,"Mar 2022, Page 13, antiviral resistance, Table 2",Pseudovirus,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,P.1 Spike,"Mar 2022, Page 13, antiviral resistance, Table 2",Pseudovirus,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,B.1.617.2 Spike,"Mar 2022, Page 13, antiviral resistance, Table 2",Pseudovirus,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,B.1.617.2 Spike:+417N,"Mar 2022, Page 13, antiviral resistance, Table 2",Pseudovirus,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,B.1.427/9 Spike,"Mar 2022, Page 13, antiviral resistance, Table 2",Pseudovirus,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,B.1.526/E484K Spike,"Mar 2022, Page 13, antiviral resistance, Table 2",Pseudovirus,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,B.1.617.1 Spike,"Mar 2022, Page 13, antiviral resistance, Table 2",Pseudovirus,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,C.37 Spike,"Mar 2022, Page 13, antiviral resistance, Table 2",Pseudovirus,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,B.1.621 Spike,"Mar 2022, Page 13, antiviral resistance, Table 2",Pseudovirus,IC50,=,5.3,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,BA.1 Spike,"Mar 2022, Page 13, antiviral resistance, Table 2",Pseudovirus,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,BA.1 Spike:+346K,"Mar 2022, Page 13, antiviral resistance, Table 2",Pseudovirus,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,BA.2 Spike,"Mar 2022, Page 13, antiviral resistance, Table 2",Pseudovirus,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,B.1.1.7 full genome,"Mar 2022, Page 14, antiviral resistance, Table 3",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,B.1.351 full genome,"Mar 2022, Page 14, antiviral resistance, Table 3",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,P.1 full genome,"Mar 2022, Page 14, antiviral resistance, Table 3",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,B.1.617.2 full genome,"Mar 2022, Page 14, antiviral resistance, Table 3",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,B.1.427 full genome,"Mar 2022, Page 14, antiviral resistance, Table 3",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,B.1.526 full genome/E484K,"Mar 2022, Page 14, antiviral resistance, Table 3",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,Omicron/BA.1 full genome,"Mar 2022, Page 14, antiviral resistance, Table 3",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-28
FDA22,Bebtelovimab,Wuhan-Hu-1,Omicron/BA.1+R346K full genome,"Mar 2022, Page 14, antiviral resistance, Table 3",Virus isolate,IC50,=,1,NULL,NULL,1,2022-03-28
